In this podcast, Sharlene Jenner, vice president of engagement strategy at Abelson Taylor and professor of AI and personalization for digital marketers at Southern Methodist University, leads a panel of five industry leaders in a roundtable discussion. The conversation delves into the practicalities of current AI applications and confronts the ethical and regulatory issues related to the technology. The panelists also explore the direct consequences and prospective implications of AI, providing listeners with a snapshot of the present and an outlook on the transformative potential of emerging technologies in the pharmaceutical marketing sphere. 

The panel consists of: Faruk Capan, chief innovation officer, EVERSANA, and CEO, EVERSANA INTOUCH; Anurag Banerjee, CEO and founder, Quilt.AI; Jeff Headd, vice president, commercial data science, The Janssen Pharmaceutical Companies of Johnson & Johnson; and Stephen Onikoro, senior principal, head of strategy, PharmaForceIQ.

Sponsored by: ZS https://www.zs.com/

Pharma Marketing in the Age of AI: A New Era Begins

Synopsis:

Dive into this episode of Biotech 2050 where host Rahul Chaturvedi interviews Jeb Keiper, CEO of Nimbus Therapeutics. Discover Jeb's fascinating journey from MIT chemist to industry leader, and the unique strategies that have driven Nimbus's success. Jeb discusses the evolution of biotech financing, the importance of taking bold risks, and the innovative approaches Nimbus employs in drug development. He also shares insights on building a resilient team, navigating challenging capital markets, and fostering a collaborative ecosystem in biotech. This episode provides valuable lessons for aspiring biotech leaders and a deep dive into the intricacies of managing a cutting-edge biotech company.

Biography:

Jeb Keiper, M.S., M.B.A., has served as our President and Chief Executive Officer and as a member of our board of directors since October 2018. He previously served as Chief Business Officer from November 2014 to October 2018 and as Chief Financial Officer from February 2017 to October 2018. Since joining Nimbus, Mr. Keiper has overseen the discovery and development of three programs into clinical testing across a range of indications, over $400M raised in equity funding, executed deals worth over $7B, and the return of over $4B in gains back to equity holders.
Prior to joining Nimbus, Mr. Keiper served as the Vice President of Business Development at GSK Oncology (a subsidiary of GlaxoSmithKline plc (NYSE: GSK)) from March 2011 to October 2014, where he was responsible for identifying and concluding several critical collaborations for GSK in Oncology, including the Novartis-GSK Oncology integration, and spent a decade at GSK in various business development leadership roles. Prior to GSK, Mr. Keiper was a consultant at McKinsey & Company starting in September 2000-2002, then September 2004 to 2005, after having started his career as a pharmaceutical chemist at Pfizer Inc. (NYSE: PFE) in 1998.
Mr. Keiper currently serves as a member of the board of directors at private biotechnology companies Cardurion Pharmaceuticals, Inc., and ROME Therapeutics, Inc.
Mr. Keiper received two B.S. degrees, one in Chemistry and one in Chemical Engineering, as well as an M.S. in Chemical Engineering from the Massachusetts Institute of Technology, and an M.B.A. from the MIT Sloan School of Management with joint program in Biomedical Enterprises with the Harvard Medical School.

Biotech Breakthroughs: Jeb Keiper, CEO of Nimbus Therapeutics, Discusses Their Innovative Journey

In this insightful interview, Dr. Sathish, Head of R&D at Anthem, shares his fascinating journey from academia to leading one of India's top CROs. Learn about his early passion for biology, his groundbreaking work in virology, and his transition back to India to build a thriving R&D division.

Dr. Sathish discusses the evolving role of CROs, the impact of AI in research, and the future of R&D in India.

Emotional return to India, Dr. Sathish shares his inspiring experience | #E02 Pharma Now

Synopsis: 

Join host Alok Tayi as he welcomes David Meeker, CEO of Rhythm Pharmaceuticals, for an inspiring conversation on the transformative journey of rare disease biotech. David shares his incredible path from practicing physician to biotech visionary, recounting his experiences at Genzyme, where he helped shape the rare disease business model and set the stage for a wave of life-changing innovations.  

In this episode, David dives deep into the breakthroughs and hurdles of developing therapies for rare diseases, the pivotal role of patient-centric approaches, and how advancements in precision medicine are reshaping treatment for conditions like genetic obesity. He also explores the evolving relationship between biotech and big pharma, the critical impact of regulatory decisions, and the essential elements of building a thriving biotech company today.  

Don’t miss this captivating discussion packed with actionable insights, industry wisdom, and a look at the future of rare disease therapeutics.

Biography:

Dr. David Meeker, a member of Rhythm’s Board of Directors since 2015 and Chairman of the Board since 2017, was appointed President and Chief Executive Officer of the Company in July 2020. Most recently, he served as President and CEO of KSQ Therapeutics for approximately three years. Previously, David was the Executive Vice President and Head of Sanofi Genzyme, the specialty-care global business unit of Sanofi that focused on rare diseases, multiple sclerosis, oncology, and immunology. He joined Genzyme in 1994 as Medical Director and, over the course of his tenure, served the company as Vice President of Medical Affairs, Chief Operating Officer, and Chief Executive Officer. He led Genzyme’s commercial organization and global market access functions and managed the launch of several treatments for rare genetic diseases, including Aldurazyme®, Fabrazyme® and Myozyme®. Prior to his tenure with Genzyme, David was Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an Assistant Professor of Medicine at Ohio State University. Dr. Meeker earned his MD from the University of Vermont Medical School and completed the advanced management program at Harvard Business School.

David Meeker, CEO of Rhythm Pharmaceuticals, on Rare Disease Breakthroughs & Biotech’s Future

"In This Episode"

In this episode, we dive deep into how AI is reshaping the pharmaceutical manufacturing landscape with Harini Gopalakrishnan. From improving operational efficiency to leveraging predictive analytics and generative content, Harini shares her expertise on driving smarter, faster, and more accurate decisions in this critical industry. 

Harini Gopalakrishnan is a seasoned professional with 17+ years of experience at the intersection of life sciences and technology. She has worked across various sectors including consulting, pharma, CRO, and tech, gaining expertise in product innovations, strategic partnerships, and tech interventions. Known for her energy, drive, and entrepreneurial mindset, she excels at creating strategic alliances with organizational leaders to align and support key business initiatives. Harini was the winner of the Gartner Award in 2020 for the "Innovative Use of an Emerging Technology in Pharma and Life Sciences.”


"Revolutionize Your Biomanufacturing with Katalyze AI"

Experience how Katalyze AI’s platform can transform your operations by enhancing yield, improving traceability, and reducing cycle times across your biopharma processes.


"Here’s What You Can Achieve"

Up to 8% Yield Increase: Minimize deviations and optimize quality with AI-powered digital twins tailored to your processes.
40% Faster Batch Release: Streamline raw material quality control by automating data consolidation and specification checks.
Save Up to 4 Hours on Investigations: Leverage a unified source of truth for raw material and process data to quickly identify root causes and draft reports.


"Get Your Free Demo Today"

Curious about how Katalyze AI can elevate your manufacturing operations? Fill out the form, and our team will provide a tailored demonstration to discuss solutions specific to your needs.


"Key Features Include"

- More Than 10+ out-of-the-box Integrations
- Access to Katalyze AI's Large Biologic Models
- Science-Backed Yield and Quality Improvement

Book Your Free Demo Now: https://katalyzeai.com/contactus




Driving Pharma Innovation with AI: A Conversation with Harini Gopalakrishnan

Pharma Now is one of the leading monthly B2B magazines publishing premium content relevant to the pharma industry since 2007, providing comprehensively unique coverage of news stories, interviews, features, and analysis on the pharma & biopharma sector by its leading editorial panel.

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.

New tracks tagged #PharmaInnovation